

Resource Summary Report

Generated by [dkNET](#) on Aug 26, 2026

CHLA-02-ATRT

RRID:CVCL_B045

Type: Cell Line

Proper Citation

ATCC Cat# CRL-3020, RRID:CVCL_B045

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_B045

Proper Citation: ATCC Cat# CRL-3020, RRID:CVCL_B045

Description: Cell line CHLA-02-ATRT is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Atypical teratoid/rhabdoid tumor

Defining Citation: [PMID:25211508](#), [PMID:25638158](#)

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: CHLA-02-ATRT

Synonyms: CHLA-02

Cross References: ATCC:CRL-3020, BioSample:SAMN03471711, Wikidata:Q54812138

ID: CVCL_B045

Vendor: ATCC

Catalog Number: CRL-3020

Record Creation Time: 20220427T215458+0000

Record Last Update: 20260815T232036+0000

Ratings and Alerts

No rating or validation information has been found for CHLA-02-ATRT.

No alerts have been found for CHLA-02-ATRT.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Merk DJ, et al. (2024) Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors. *Genome biology*, 25(1), 301.

Metselaar DS, et al. (2024) Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors. *Cell reports. Medicine*, 5(9), 101700.

Hofman DA, et al. (2024) Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. *Molecular cell*, 84(2), 261.

Hofman DA, et al. (2023) Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. *bioRxiv : the preprint server for biology*.

Parkhurst A, et al. (2022) Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors. *Cell death & disease*, 13(4), 410.

Leruste A, et al. (2019) Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors. *Cancer cell*, 36(6), 597.

Wang SZ, et al. (2019) Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 25(19), 5925.